| [1] Stupp R,Hegi ME,Mason WP,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol,2009,10(5):459-466.[2] Belcaid Z,Phallen JA,Zeng J,et al.Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model[J].PLoS One,2014,9(7):e101764.[3] Weller M,Cloughesy T,Perry JR,et al.Standards of care for treatment of recurrent glioblastoma-are we there yet?[J].Neurol Oncol,2013,15(1):4-27.[4] Nirschl CJ,Drake CG.Molecular pathways:coexpression of immune checkpoint molecules:signaling pathways and implications for cancer immunotherapy[J].Clin Cancer Res,2013,19(18):4917-4924.[5] Tahtinen S,Kaikkonen S,Merisalo-Soikkeli M,et al.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors[J].PLoS One,2015,10(6):e131242.[6] Zhang S,Ke X,Zeng S,et al.Analysis of CD8+Treg cells in patients with ovarian cancer:a possible mechanism for immune impairment[J].Cell Mol Immunol,2015,12(5):580-591.[7] Gilbert MR,Dignam JJ,Armstrong TS,et al.A randomized trial of bevacizumab for newly diagnosed glioblastoma[J].N Engl J Med,2014,370(8):699-708.[8] Chinot OL,Wick W,Mason W,et al.Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma[J].N Engl J Med,2014,370(8):709-722.[9] Demaria S,Kawashima N,Yang AM,et al.Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer[J].Clin Cancer Res,2005,11(2 Pt 1):728-734.[10] Leach DR,Krummel MF,Allison JP.Enhancement of antitumor immunity by CTLA-4 blockade[J].Science,1996,271(5256):1734-1736.[11] Quezada SA,Simpson TR,Peggs KS,et al.Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts[J].J Exp Med,2010,207(3):637-650.[12] Peggs KS,Quezada SA,Chambers CA,et al.Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies[J].J Exp Med,2009,206(8):1717-1725.[13] Vanpouille-Box C,Pilones KA,Wennerberg E,et al.In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment[J].Vaccine,2015,33(51):7415-7422. |
